TEVA — Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Q2 Revenues: Approximately $4.1 billion, down 1% YoY (3% in local currency), primarily due to lower generics revenue.
• Net Loss: $576 million, or $0.49 per share.
• Non-GAAP Gross Margin: 55.4%, up 80 basis points YoY.
• Non-GAAP Operating Margin: 9% (26.6% excluding MLX acquisition expenses).
• Non-GAAP EPS: $0.02 (adjusted EPS would have been $0.63 without MLX impact).
• Free Cash Flow: $622 million, up 31% YoY.
• Net Debt: $12.9 billion, with a net debt-to-EBITDA ratio of 2.8x (2.3x excluding MLX).

2. Strategic Updates and Business Highlights

• Growth Strategy: Teva's pivot to growth strategy, initiated in 2023, focuses on four pillars: innovative product delivery, pipeline innovation, generics strength, and capital allocation.
• Innovative Portfolio Performance: Strong growth in key products:
  • AUSTEDO: Revenue up 40% YoY, now projected to reach $2.45 billion to $2.6 billion.
  • UZEDY: Revenue up 43% YoY, with new guidance of $270 million to $290 million.
  • AJOVY: Revenue up 56% YoY, with new guidance of $850 million to $870 million.
• Biosimilars: 15 products in the market and 14 in the pipeline, with expectations to exceed $800 million in revenue by 2027.
• Acquisition of Amylyx: Closed in June, expected to launch in 2027 pending FDA approval.
• Credit Rating Upgrade: Fitch upgraded Teva to investment grade, marking a return to IG status for the first time since 2017.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year revenue guidance raised by $75 million, reflecting strong performance in innovative products.
• Operating Income and EBITDA: Guidance reaffirmed, with expectations for continued margin improvement driven by innovative product growth.
• Long-term Goals: Targeting a 30% operating margin by 2027 and a net debt-to-EBITDA ratio below 2x.

4. Challenges and Points of Concern

• Generics Decline: Generics revenue down 15% YoY, primarily due to the loss of generic REVLIMID.
• Inventory Levels: Elevated inventory levels for AUSTEDO, impacting revenue expectations for Q3 and Q4.
• Market Competition: Increased competition in generics and potential pricing pressures due to the IRA implementation in 2026.
• Softness in Europe: Lower-than-expected performance in Europe attributed to fewer high-value launches and a weak cough and cold season.

5. Notable Q&A Insights

• AUSTEDO Pricing and Payer Dynamics: Confidence in maintaining market share despite potential pricing pressures from competitors due to IRA negotiations.
• Celiac Disease Study: Anticipated data readout in the second half of 2026, with a focus on significant gluten challenges in study design.
• Biosimilars Growth: Teva's growing biosimilars portfolio is expected to be a major growth driver, with strong early performance in the U.S. and Europe.
• Launch Preparations: Emphasis on thorough preparations for upcoming launches of olanzapine and ecopipane, leveraging existing expertise in the market.

Overall, Teva is navigating a complex landscape with a strong focus on innovative product growth while addressing challenges in its generics business and market competition.